Voyager Therapeutics stock rockets after license option deal with Pfizer that could be valued at $630 million

Shares of Voyager Therapeutics Inc. VYGR, -3.52% rocketed 38.9% successful premarket trading Wednesday, aft closing astatine a grounds debased successful the erstwhile session, aft the cistron therapy institution announced a licence enactment statement with Pfizer Inc. PFE, -0.24% that could valued astatine much than $600 million. Trading measurement spiked up to 3.9 cardinal shares up of the open, which compares with the full-day mean of astir 173,000 shares. The statement allows Pfizer to workout options to licence caller capsids generated from Voyager's RNA-driven screener technology, which would beryllium utilized by Pfizer to develop, marque and commercialize cistron therapies. As portion of the agreement, Voyager volition person an upfront outgo of $30 million, and is entitled to person up to $20 cardinal successful workout fees. Voyager volition besides beryllium eligible to person up to $580 cardinal successful milestone payments, and volition beryllium eligible to person "mid- to high-single-digit tiered royalties" based connected income of Pfizer products utilizing the licensed capsids. The stock, which closed astatine a grounds debased of $2.47 connected Tuesday, has tumbled 36.5% implicit the past 3 months portion the S&P 500 SPX, +1.05% has inched up 0.1%.